(Q37486921)

20 August 2017

1 reference

title

ISCOMs and ISCOMATRIX. (English)

1 reference

20 August 2017

Hong-Xiang Sun

1

1 reference

20 August 2017

Yong Xie

series ordinal

2

1 reference

20 August 2017

Yi-Ping Ye

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

28 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

27

1 reference

20 August 2017

33

1 reference

20 August 2017

4388-4401

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

20 August 2017

1 reference

Liposomes and ISCOMS as vaccine formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMATRIX adjuvant for antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOM-based vaccines: the second decade.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Saponin-adjuvanted particulate vaccines for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immune responses to ISCOM formulations in animal and primate models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Current status and potential application of ISCOMs in veterinary medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMs and other saponin based adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Saponins from Quillaja saponaria Molina: Isolation, Characterization and Ability to Form Immuno Stimulatory Complexes (ISCOMs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Adjuvanticity and ISCOM formation by structurally diverse saponins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

In vivo and in vitro lipidation of recombinant immunogens for direct iscom incorporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

On the preparation, microscopic investigation and application of ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunomodulation by iscoms, immune stimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMs (immunostimulating complexes): the first decade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immuno-stimulating complexes prepared by ethanol injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

A comparison of pseudo-ternary diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by lipid-film hydration and dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Incorporation of ovalbumin into ISCOMs and related colloidal particles prepared by the lipid film hydration method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Quil A-lipid powder formulations releasing ISCOMs and related colloidal structures upon hydration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Preparation of immuno-stimulating complexes (ISCOMs) by ether injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOM based vaccines for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Cage-like complexes formed by DOTAP, Quil-A and cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

General strategies for efficient adjuvant incorporation of recombinant subunit immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Local immune responses following nasal delivery of an adjuvanted influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Effect of priming on subsequent response to inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunogenicity and efficacy of recombinant subunit vaccines against phocid herpesvirus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Purification of phocid herpesvirus type 1 glycoproteins B and D and pilot studies of immunogenicity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Serum antibody responses to equine herpesvirus 1 glycoprotein D in horses, pregnant mares and young foals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Vaccination prevents latent HSV1 infection of mouse brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Use of cotton rats for preclinical evaluation of measles vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Bovine respiratory syncytial virus ISCOMs--protection in the presence of maternal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Rinderpest virus (RPV) ISCOM vaccine induces protection in cattle against virulent RPV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immune response of BALB/c mouse immunized with recombinant MSPs proteins of Anaplasma marginale binding to immunostimulant complex (ISCOM).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOM vaccine against contagious bovine pleuropneumonia (CBPP). 1. Biochemical and immunological characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Experimental field trial with an immunostimulating complex (ISCOM) vaccine against contagious bovine pleuropneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Evaluation of ISCOMATRIX and ISCOM vaccines for immunisation against Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Prevention of naturally occurring infectious bovine keratoconjunctivitis with a recombinant Moraxella bovis pilin-Moraxella bovis cytotoxin-ISCOM matrix adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunisation of mice against neosporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Toxoplasma gondii: isolation of tachyzoites rhoptries and incorporation into Iscom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Partial protection against tissue cysts formation in pigs vaccinated with crude rhoptry proteins of Toxoplasma gondii.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of lymphocyte recruitment in the absence of a detectable immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Immunostimulating complexes (ISCOMs) for nasal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

New horizons in adjuvants for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Phagosomes are competent organelles for antigen cross-presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus iscoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Quillaja saponin formulations that stimulate proinflammatory cytokines elicit a potent acquired cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

ISCOMs: an adjuvant with multiple functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Early IL-4 production does not predict susceptibility to Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Cytotoxic T cell polyepitope vaccines delivered by ISCOMs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Induction of cell death by saponin and antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

inferred from DOI database lookup

7 January 2021

based on heuristic

Mechanism and regulation of immunoglobulin isotype switching.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.032

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.05.032

1 reference

20 August 2017

1 reference